Clinical Study
Long-Term Mortality Analysis in Parkinson’s Disease Treated with Deep Brain Stimulation
Table 1
Comparison between deceased patients and survivors.
| | | Deceased patients | Nondeceased patients | value |
| | Male gender: (%) | 13 (86.67) | 100 (59.17) | 0.032 | | Age at disease onset (mean, years) | | | 0.707 | | Akinetic-rigid phenotype: (%) | 8 (53.33) | 103 (60.95) | 0.564 | | Age at the time of DBS (mean, years) | | | 0.894 | | Disease duration until DBS (mean, years) | | | 0.751 | | UPDRS part III before surgery without L-dopa medication (mean) | | | 0.399 | | UPDRS part III before surgery with L-dopa medication (mean) | | | 0.083 | | Motor benefit after surgery (mean, %) | | | 0.0004 |
|
|
